$16.24
4.47% day before yesterday
Nasdaq, Oct 03, 10:10 pm CET
ISIN
US42328V5049
Symbol
HSDT

Helius Medical Technologies Inc Class A Stock price

$16.24
+10.35 175.72% 1M
-283.76 94.59% 6M
-486.49 96.77% YTD
-381.86 95.92% 1Y
-10,483.76 99.85% 3Y
-517,765.01 100.00% 5Y
-4,902,171.26 100.00% 10Y
-14,189,421.26 100.00% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
-0.76 4.47%

Key metrics

Basic
Market capitalization
$17.5m
Enterprise Value
$11.4m
Net debt
positive
Cash
$6.1m
Shares outstanding
680.0k
Valuation (TTM | estimate)
P/E
negative | negative
P/S
58.3 | 45.8
EV/Sales
38.1 | 29.9
EV/FCF
negative
P/B
2.9
Financial Health
Equity Ratio
29.9%
Return on Equity
-1,108.8%
ROCE
-239.3%
ROIC
-3,163.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$300.0k | $381.5k
EBITDA
$-14.5m | -
EBIT
$-14.6m | $-14.6m
Net Income
$-21.3m | $-175.8m
Free Cash Flow
$-11.4m
Growth (TTM | estimate)
Revenue
-49.2% | -26.6%
EBITDA
-20.9% | -
EBIT
-20.4% | -5.0%
Net Income
-140.8% | -1,397.7%
Free Cash Flow
-175.7%
Margin (TTM | estimate)
Gross
-89.2%
EBITDA
-4,928.8% | -
EBIT
-4,932.2%
Net
-7,215.3% | -46,090.9%
Free Cash Flow
-3,878.6%
More
EPS
$-172.6
FCF per Share
$-16.8
Short interest
1.4%
Employees
21
Rev per Employee
$20.0k
Show more

Is Helius Medical Technologies Inc Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Helius Medical Technologies Inc Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Helius Medical Technologies Inc Class A forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Helius Medical Technologies Inc Class A forecast:

Hold
50%
Sell
50%

Financial data from Helius Medical Technologies Inc Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.30 0.30
49% 49%
100%
- Direct Costs 0.56 0.56
8% 8%
187%
-0.26 -0.26
425% 425%
-87%
- Selling and Administrative Expenses 10 10
17% 17%
3,490%
- Research and Development Expense 3.77 3.77
24% 24%
1,257%
-15 -15
21% 21%
-4,847%
- Depreciation and Amortization 0.01 0.01
80% 80%
3%
EBIT (Operating Income) EBIT -15 -15
20% 20%
-4,850%
Net Profit -21 -21
141% 141%
-7,097%

In millions USD.

Don't miss a Thing! We will send you all news about Helius Medical Technologies Inc Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Helius Medical Technologies Inc Class A Stock News

Neutral
GlobeNewsWire
6 days ago
HSDT Solana Company's Mission is to maximize SOL per share on one of the most commercially viable blockchains for consumer applications while delivering consistent on-chain yield for investors
Neutral
GlobeNewsWire
10 days ago
Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device Designation Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device Designation
Neutral
GlobeNewsWire
13 days ago
NEWTOWN, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (the "Company" or "HSDT"), today announced its first acquisition of Solana (“SOL”) tokens as part of its digital asset treasury strategy under which the principal holding will be SOL, the native digital asset of the Solana Blockchain. The Company now holds over 760,190 SOL, with an average cost basis of $231. The...
More Helius Medical Technologies Inc Class A News

Company Profile

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain's ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

Head office United States
CEO Dane Andreeff
Employees 21
Founded 2014
Website heliusmedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today